FdaApplication
BLA 125773
Identifiers
- fda_app_no: BLA125773
Properties
| Property | Value |
|---|---|
| applicant_name | Iovance Biotherapeutics, Inc. |
| application_type | BLA |
| approval_date | 2024-02-16 |
Revenue by product
AMTAGVI
| Period | Revenue |
|---|---|
| Q2 2026 | $90.7M |
| Q1 2026 | $60.2M |
| Q4 2025 | $64.9M |
| Q3 2025 | $57.5M |
| Q2 2025 | $54.1M |
| Q1 2025 | $43.6M |
| Q4 2024 | $48.7M |
| Q3 2024 | $42.0M |
| Q2 2024 | $12.8M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| AMTAGVI | — | 7.5x10^9 to 72x10^9Cells | Suspension |
1 product